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Futile chemotherapyAbstract Background: This study evaluates the use of palliative chemotherapy (PCT) and possible
associated factors at the end of life.
Method: The study includes all advanced non hematological cancer patients who died in the King
Abdullah Medical City during the period from January 2011 to April 2014. Demographic and dis-
ease features were registered.
Results: 420 patients were included in the study, median age 62 years (range 17–108); 52% female
and 48% male. 87.4% of patients were Saudis and 12.6% non Saudis.
124 (29.5%) patients received PCT at the last month before death (LM-PCT): 21.8%, 22.6% and
55.6% within one, two and four weeks of death, respectively. Place of death (critical care vs. regular
ward) and mode of admission (ER vs. OPD vs. Transferred) had a strong association with LM-PCT
(p< 0.0001, /= 0.35) and (p< 0.0001, V= 0.43), respectively. There was a gradual increase in
the number of patients receiving LM-PCT from January 2011 to April 2014; 15.3%, 28.2%,
37.1% and 19.4%, respectively.
Conclusion: In our center; at the end of life, there is a gradual increase in the number of patients
receiving chemotherapy which signiﬁcantly increased cancer patients’ odds without clear predictive
factors associated with its use, which calls into question the beneﬁts of PCT in terminally ill cancer
patients.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chemotherapy for metastatic solid tumors such as lung,
breast, colon, or prostate cancer rarely if ever cures patients.
The indication for such chemotherapy is to improve disease-
free or overall survival, relieve symptoms, and improve the
36 A.A. Mohammed et al.quality of life. Palliative chemotherapy (PCT) accounts for
most of the work of everyday oncology given the rarity of
curable disease, it may even shorten a patient’s life [1].
Many studies demonstrated that PCT given in the last mon-
th of life (LM-PCT) is increasing and treatment frequencies
from 9% to 43% have been reported [2,3].
LM-PCT was recognized by The American Society of
Clinical Oncology to be one of the top-ﬁve practices that could
improve patients’ care and reduce costs, if stopped.
More than 20% of patients receiving Medicare who had
metastatic cancer started chemotherapy treatment in the
2 weeks before death [4], with no clear predictive factors asso-
ciated with this use [5,6]. On the other hand, some studies have
shown that ceasing aggressive cancer treatments earlier by
introducing palliative care can increase the survival time and
quality of life in patients with lung cancer [7].
As we were interested in how to adjust the use of futile che-
motherapy in terminal patients, this pushed us to investigate
the current practice in the King Abdullah Medical City
(KAMC); Saudi Arabia, to determine the proportion of
patients with metastatic cancer who ever received PCT and
the proportion of those who received chemotherapy within 2
and 4 weeks of death and to evaluate if there are any predictive
factors to start PCT at the end of life. A secondary aim was to
identify the potential drawback of ongoing PCT in the last
month of life.
Materials and methods
The current retrospective cohort design included 429 advanced
cancer patients who died in the KAMC during the period from
January 2011 to April 2014.
PCT was deﬁned as chemotherapy treatment with noncura-
tive intent. The eligibility criteria were; pathological diagnosis
of cancer, evidence of advanced disease and death during hos-
pitalization at KAMC.
We recorded the demographic data of patients, including
gender, age at time of death, cancer diagnosis, nationality
(classiﬁed as Saudi or non-Saudi), and place of death [8].
The data collected from patient charts and from the electronic
medical records of the Medica Plus Oncology Management
System. Patients were excluded if the cancer diagnosis was a
hematological malignancy, if they were not seen by the medical
oncology service or if they were treated with adjuvant or
curative intent.
Identiﬁed patients were divided in two groups: one group
had received PCT in the last month of life (LM group) (which
is subdivided into patients that received chemotherapy within
one, 2 and 4 weeks of death) and the other group that had
not received PCT in the last month of life (only supportive
care).
Statistical analysis
Data were analyzed using SPSS Version 15.0. The outcome
variables were the starting of PCT and continuation within
the last one, 2 and 4 weeks of life. The inﬂuence of demograph-
ic features and cancer characters were determined using the
chi-square test. P value of <0.05 denoted statistical
signiﬁcance.Results
During the study period, a total of 429 patients died with can-
cer in KAMC, 9 patients were excluded due to incomplete
data. The median age was 62 years (range 17–108); 52% female
and 48% male. 87.4% of patients were Saudis and 12.6% non
Saudis.
The following solid tumors types were represented: gastro-
esophageal cancer 84 (20.0%), colorectal cancer 61 (14.5%),
lung cancer 56 (13.3%), breast cancer 54 (12.9%), genitor-
urinary 41 (9.8), HCC 32 (7.7%), biliary tract 23 (5.5%), head
and neck 21 (5.0%), cancer unknown 20 (4.6%), gall bladder
carcinoma 10 (2.4%), sarcoma 8 (1.9%), CNS cancer 3
(0.7%), and miscellaneous 7 (1.7%).
Among the included patients, 124 (29.5%) received LM-
PCT and 296 (70.5%) were treated with best supportive care
alone. The patients that received LM-PCT were subjected to
intensive medical care in the form of frequent admission to
the hospital through ER (80.6%), and about half of those
patients died in critical care (49.2%) compared to 33.6% and
15.9% in non PCT.
Chi-square test for independence revealed that LM-PCT
had a strong association with place of death and mode of
admission. However, no association was found with age, gen-
der, tumor type and nationality (Table 1).
Of the 124 patients received LM-PCT, 63% were below
65 years old. Gender was nearly divided equally between males
and females.
Among the patients received LM-PCT, 27 patients received
PCT in the last one week of life, 28 patients in the last 2 weeks
of life and 69 patients in the last 4 weeks of life. This represents
21.8%, 22.6% and 55.6% of patients who received LM-PCT
(n= 124) respectively, and 6.4%, 6.7% and 16.4%, among
the total number of deaths (n= 420), respectively. The distri-
bution as regards each separate year was illustrated in Table 2,
and Fig. 1.
Discussion
The availability of new chemotherapeutic agents has caused a
subsequent increase in the length of time patients are receiving
chemotherapy. It is not easy to identify the role of end of life
chemotherapy. While the use of chemotherapy and its tol-
erability are increasing, balancing the risks and beneﬁts of such
a treatment is getting more complex. Ultimately, it may
involve judgments about the use or restraint of use of costly
resources despite little chance of beneﬁt [8]. Deciding when
to discontinue chemotherapy is often challenging, however,
given limited data on whether chemotherapy is helpful or
harmful in the ﬁnal months of life.
This study to my knowledge is the ﬁrst to describe the pat-
tern of PCT utilization and continuation until the end of life in
King Saudi Arabia. This study revealed that, among the
patients with advanced cancer; 29.5% received LM-PCT. Mul-
tiple studies reported the increase of PCT practice. In Italy,
within 30 days of death, 23% of patients with incurable cancer
received PCT [6]. This was within the range of previous pub-
lished results, 18–33% [9–11].
Among the identiﬁed patients who had been received PCT,
21.8% was commenced in the last week, 22.6% in the last
Table 1 Patients characteristics in LM.
Parameters LM-PCT status N; 420 P valuea
Not received PCT Received PCT
N; 296 (70.5%) N; 124 (29.5%)
Age (years)
<65 160 (67.2%) 78 (32.8%) 0.095
P65 136 (74.7%) 46 (25.3%)
Gender
Male 141 (70.1%) 60 (29.9%) 0.94
Female 153 (70.5%) 64 (29.5%)
Nationality
Saudi 259 (70.6%) 108 (29.4%) 0.9
Non Saudi 37 (69.8%) 16 (30.2%)
Mode of admission
ERb 99 (49.7%) 100 (50.3%) <0.0001
OPDc 186 (89%) 23 (11%)
Transferred 10 (90.9%) 1 (9.1%)
Place of death
Critical care; (ICUd,CCUe, ER) 47 (43.5%) 61 (56.5%) <0.0001
Regular ward 249 (79.8%) 63 (20.2%)
Chi-square test for independence revealed that LM-PCT had strong association with place of death, i.e., critical care wards vs. regular wards and
mode of admission, i.e., ER, OPD and direct transferred from other heath care facilities (v2 (1df, N= 420) = 50.8, p< 0.0001, /= 0.35) and
(v2 (2df, N= 419) = 77.6, p< 0.0001, V= 0.43), respectively. However, no association was found with age, i.e., <65 and P65 (v2 (1df,
N= 420) = 2.8, p= 0.09); gender, i.e., male and female (v2 (1df, N= 420) = 0.006, p= 0.93); tumor type (v2 (1df, N= 420), p= 0.3) and
nationality, i.e., Saudis and non Saudis (v2 (1df, N= 420) = 0.007, p= 0.94).
a P, value 60.05 signiﬁcant.
b ER; emergency room.
c OPC; outpatient department.
d ICU; intensive care unit.
e CCU; cardiac care unit.
Table 2 Pattern of LM-PCT* during the study period.
Duration (days before death) No. of patients died Total/%
2011 2012 2013 2014**
0–7 6 10 9 2 27 (21.8%)
8–14 5 6 12 5 28 (22.6%)
15–30 8 19 25 17 69 (55.6%)
Total/% 19 (15.3%) 35 (28.2%) 46 (37.1%) 24 (19.4%) 124 (100%)
* Palliative chemotherapy in the last month.
** Till April 2014.
Palliative chemotherapy at end-of-life 372 weeks and 55.6% in the last 4 weeks of life, compared with
8% in the Australian population and 18.5% in the North
America population in the last 2 weeks of life [12].
During the study period, we observed a progressive increase
in the number of LM-PCT; 19 patients (15.3%) in 2011, 35
patients (28.2%) in 2012, 46 patients (37.1%) in 2013 and 24
patients (19.4%) in ﬁrst 4 months of 2014 (till April 2014).
The possible explanations to account for the higher rate
and progressive increase in futile chemotherapy in our country
include, limited access to hospice and palliative care services
for all patients, the new era of using targeted therapy as
longer- term maintenance treatment could be one of the justi-
ﬁcations for patients receiving therapy nearer to the time of
death. Moreover, our patients who received PCT were less
likely to acknowledge that they were terminally ill and may
not ﬁnd it easy to accept their condition, in addition to some
emotional and religious factors; the oncologist may ﬁnd it hard
to deliver this information to the patients or their caregivers,which is in agreement with other studies; On 95 consecutive
patients receiving PCT, prognosis was discussed by only
39% of medical oncologists [13], and in other studies, about
one third of patients and families reported, they did not believe
in the concept of PCT [14,15].
In the present study, more than half (63%) of the patients
with metastatic disease started LM-PCT; with age <60 years
old which matches with many other studies [16–18], however,
some studies show that the performance status is the most
important issue for treatment results, not the age which is
not evaluated in our study [19–21].
Also, patients received LM-PCT were subjected to intensive
medical care in the form of frequent admission to the hospital
through ER (80.6%), and about half of those patients died in
critical care (49.2%) compared to 33.6% and 15.9% in non
PCT, which is statistically signiﬁcant. However, no association
was found between age, gender, type of tumor or nationality
and starting PCT. These results are consistent with studies
Figure 1 Illustrate palliative chemotherapy in the last month (LM-PCT) in days during the study period. *2014; not the whole year, only
till April.
38 A.A. Mohammed et al.done by Earle et al. [4] and Nappa et al. [22]. Similarly, Write
et al. demonstrated that in terminal cancer patients who
received chemotherapy in the last months of their lives are less
likely to die where they want and are more likely to experience
painful, aggressive procedures. These patients saw no survival
beneﬁts from end-of-life chemotherapy but they faced higher
rates of cardiopulmonary resuscitation, mechanical ventila-
tion, or both, during their last week of life (14% vs. 2%). Also
more died in ICU (11% vs. 2%) [23].
Whether these unfavorable outcomes were a result of dis-
ease progression or caused by the last cycle of PCT cannot
be concluded in this study.
It is not a regional observation, it is found in many studies
from multiple countries revealing that patients with cancer pre-
ferred aggressive treatment even with major adverse effects for
doubtful beneﬁt [24].
Limitations
The use of one month as cut off may be questioned. But this
time frame of has been used in other published studies
[6,7,9,11,12,23,25–28]. Retrospective studies most always are
criticized as the completeness of data often is suboptimal
and depends totally on medical documentation without
matched controls beside the limited information about patients
that died outside the hospital. Data on performance status
could not be reviewed in medical records which is an important
factor in PCT selection.
Conclusion & recommendation
Our data demonstrated an increased use of chemotherapy near
or at the time of death without apparent guidelines for its use.
We are in need to better assessment of each patient’s prognosticfactors at the time of chemotherapy. Also oncologists should
note the availability of hospice and palliatives from the begin-
ning, as part of routine good care of the seriously ill patient
and must improve their skills in helping patients think clearly
about the appropriateness of PCT.
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